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Stage
CharacteristicsGender
Male 3
Female 10Age at Diagnosis
Mean 43 years
Median 43 years (range 34-48)Diagnosis
Multiple Myeloma 12
POEMS syndrome 1Feature n (%)
HGB < 100 g/L 6/13 (46.4)
Calcium > 2.75 mmol/L 1/13 (7.6)
Creatinine > 90 mmol/L 5/13 (38.5)
Albumin < 35 g/L 7/13 (53.8)
One or more lytic lesions 9/13 (69.2)
Clonal plasma cells > 10% 8/13 (61.5)
b2-microglobulin
< 3.5 mg/L 4/13 (30.8)
3.5 mg/L - 5.5 mg/L 4/13 (30.8)
> 5.5 mg/L 5/13 (38.5)
Measurable M-protein 8/13 (61.5)Monoclonal protein
IgG 8/13 (61.5)
IgM 0/13
IgA 0/13Light Chains
kappa 5/13 (38.5)
lambda 6/13 (46.4)ISS
Stage 1 4/13 (30.8)
Stage 2 4/13 (30.8)
Stage 3 5/13 (38.5)256
SINGLE VERSUS TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) FOR MULTIPLE MYELOMA PATIENTS AND ROLE OF SECOND SAL-
VAGE TRANSPLANT: A SINGLE CENTER PROSPECTIVE PHASE II STUDY
Moreb, J.S.1, Salmasinia, D.1, Leather, H.1, Davis, A.1, Hsu, J.W.1,
Wiggins, L.1, Cogle, C.R.1, Chang, M.N.2, Wingard, J.R.1 1University
of Florida, Gainesville, FL; 2University of Florida, Gainesville, FL
The role of tandem transplants as well as a later salvage second
transplant has been in the center of interest for manymyeloma inves-
tigators. Also, the need for tandem ASCT in patients (pts) achieving
very good partial remission (VGPR) or complete remission has not
been studied prospectively. We conducted a prospective phase II
clinical trial in which enrolledmyeloma pts are assessed after the first
ASCT and offered either 2nd tandem ASCT if they achieve# PR or
maintenance if they achieve $ VGPR. These latter pts received 2nd
salvage transplant after relapse. The conditioning regimens used
were different for the two ASCT: Busulfan 0.75 mg/kg PO q 6 hr
days -8 through -5, Cyclophosphamide (CP) 60 mg/kg IV days -3
and -2, and Etoposide 10 mg/kg IV days -4 to -2 for the first
ASCT, and 96 hr (days -6 to -3) continuous IV CP 6 gr/m2 and total
body irradiation (TBI) 600 cGy (days -2 and -1) for the second
ASCT. Etoposide was omitted if pts were $ 65 year old, and TBI
was substituted by melphalan 140 mg/m2 if prior radiation did not
allow TBI. Between the years 2001-2009, 76 pts were enrolled. Of
the 31 pts planned to have tandem ASCT, 20 received tandem
ASCT and 2 additional pts had tandem auto-allo transplants. The
primary reasons for not receiving the planned tandem ASCT were
lack of socioeconomic resources and physical co-morbidities. Main-
tenance treatment was offered to both groups of pts. There were no
treatment related mortalities in the ASCT pts. We compared the
progression-free (PFS) and overall (OS) survival following the first
ASCT between pts who received tandem ASCT (n 5 20) and pts
who received single ASCT (n 5 54). The median PFS for tandem
pts was 27 mo (range, 10-93) versus 28 mo for single ASCT (range,
4-99) (P 5 0.889); the OS was 38 mo (range, 11-120) versus 72 mo
(range, 5-136), respectively (P 5 0.293). At the present time, a totalof 7 (35%) and 30 (55%) pts are still alive in the tandem and single
ASCT groups, respectively. Among the tandem pts, 2 underwent sal-
vage ASCT and one non-myeloablative allogeneic transplant (allo-
SCT); while in the single ASCT group 6 had salvage ASCT and 6
had allo-SCT. All salvage transplants were done at a median of 37
mo (range, 8-91) from 1st ASCT. In conclusion, pts who achieve $
VGPR after 1st ASCT have similar PFS and may be better OS
than pts who had tandem ASCT. Thus, the use of such response cri-
teria may identify a group of lower risk pts that will do well without
the upfront tandem ASCT.
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AUTOLOGOUS AND ALLOGENIC STEM CELL TRANSPLANTATION RE-
SULTS IN MULTIPLE MYELOMA PATIENTS – SINGLE CENTER STUDY
Ghavamzadeh, A., Alimoghaddam, K., Jahani, M., Mousavi, S.A.,
Bahar, B., Iravani, M., Ghaffari, F., Jalili, M., Jalali, A. Tehran Uni-
versity of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction:Multiplemyeloma is a hematologicmalignancywhich
best responses to high dose therapies (HDT). HDTwith autologous
stem cell transplantation (ASCT) is demonstrated for multiple mye-
loma treatment, although some studies suggest allogenic stem cell
transplantation as better choice for younger patients. Several studies
have shown the efficacy of intensive chemotherapy in increasing pro-
gression- free survival (PFS) and overall survival (OS) rates.
Patients and Methods: During study time, from 1992 till October
2011, we submitted 312 Multiple Myeloma patients. More than half
of patients weremale (male/female: 197/115).Median age of patients
was 50. They underwent autologous stem cell transplantation except
fifteen which received allogenic stem cell transplantation. Fifty six
from 297 (18.8%) ASCT followed as outpatient. ASCT patients re-
ceived high dose melphalan (100 mg/m2) for 2 days and allogenic
stem cell transplanted (ALSCT) patients were conditioned with flu-
darabin (30 mg/m2) for 5 days and melphalan (100 mg/m2) for 2
days. Nearly total of patients received stem cells via peripheral blood
source (only four received bone marrow). All patients received gran-
ulocyte colony- stimulating growth factor.
Results: During median follow up of 22 months (1-165), 280/312
(89%) are alive. Eighty eight percent of patients were in complete re-
mission before transplantation. Neutrophils (ANC$0.5 10 9/L)
and platelets ($ 20 10 9/L) recovered in median times of 12 and
18 days, respectively. Fourty percent of allogenic transplanted pa-
tients affected with acute Graft Versus Host Disease with preferable
grade I and II. In ALSCT group with median follow up of nine
months relapse was not seen. The cumulative incidence of relapse
in two years was 21.2% (CI: 15.9- 27%). Two years disease free sur-
vival (DFS) and overall survival (OS) was 75.7% (SE: 2.9%), 92.3%
(SE: 7.4%) with p5 0.422 and 89.5% (SE: 2.1%), 92.3% (SE: 7.4%)
with p 5 0.96 in ASCT and ALSCT, respectively.
Conclusion: In this retrospective study, we found that although the
two years OS were equal in two groups, but the greater DFS in
ALSCT group shows less relapse rate in this group. The median du-
ration of hematologic recovery after ASCT and ALSCT did not dif-
fer significantly. The most common cause of death in ASCT was
relapse. Similarly to other studies, relapse rate after allogenic trans-
plantation is less than autologous. There is no significant p value in
OS and DFS because of low cases of ALSCT.
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CAN PATIENTS AGE 65 AND OLDER EXPERIENCE THE SAME OUTCOMES
COMPARED TO PATIENTS YOUNGER THAN AGE 65 FOR AUTOLOGOUS
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA? A SINGLE IN-
STITUTION REVIEW
Gandhi, N., Abou Hussein, A.K., Fidler, C.J., Karur, V., Sharma, M.,
Klumpp, T.R., Kropf, P.R., Martin, M.E., Emmons, R.V.B.,
Mangan, K.F. Temple University Health System, Philadelphia, PA
High dose melphalan followed by an autologous stem cell trans-
plant has been shown to improve progression-free and overall sur-
vival in the treatment of multiple myeloma. It is unknown whether
the age of a patient receiving an autologous stem cell transplant for
multiple myeloma has an impact on treatment-related mortality
and overall outcome.
A retrospective review was performed of multiple myeloma pa-
tients transplanted at Temple Bone Marrow Transplant program
S300 Poster Session Ifrom 2000-2011. Patients included in the analysis all achieved CR1
or PR1 by CIBMTR definition prior to transplant. Patients who re-
ceived tandem transplants, allogeneic transplants, or whowere trans-
planted on clinical protocol were excluded. Disease status prior to
transplant and disease status 100 days after transplant was recorded
for both patients younger than 65 and 65 years of age and older.
Data from transplants of 117 patients were analyzed. 32 patients
(27%) were age 65 and older, and 85 patients (73%) were younger
than age 65. Prior to transplant, 20/32 patients (63%) age 65 and
above were in CR or VGPR compared to 23/85 (27%) of patients
younger than age 65. At 100-day restaging after transplant, 25/32 pa-
tients (78%) age 65 and above achieved a CR or VGPR compared to
44/85 patients (52%) younger than 65. There was one transplant-re-
lated death in each age group corresponding to a transplant-related
mortality of 3% and 1% in the older and younger age groups, respec-
tively. Two patients who were both younger than age 65 had evi-
dence of progressive disease at 100-day restaging.
Based on our single-institution analysis, multiple myeloma pa-
tients age 65 and above have experienced similar outcomes compared
to younger patients with respect to transplant-related mortality and
disease status 100-days after transplant. Specifically both age groups
experienced a consolidative benefit to high-dose therapy followed by
autologous SCT. Prospective studies evaluating the impact of age on
transplant outcome should be performed for further investigation.
Table 1. Characteristics of Myeloma Patients Transplanted at
Temple from 2000-2011Number of PatientsTable 1.
Patient # AGE
Induction pre
1st Transplant
1 46 VAD X4 then
Thalidomide
for 1 year
C
2 66 VAD X4 C
3 56 Thal/Dex then
Bro/Dex then MP
C
4 67 Lenalidomide/Dex  4 G
X indicates number of cycles; RVD, lenalidomide
Doxorubicin, Cytoxan, Etoposide; Bro, Brotezom117
Median Age 58
Range of Ages 40-77
Age 65 and greater 32
Younger than Age 65 85
Number of Males 70
Number of Females 47
IgG Subtype 62
IgA Subtype 24
Free Kappa Light Chain 16
Free Lambda Light Chain 11
Other (IgD, Oligoclonal, Non-secretory) 4
Median Time from diagnosis to BMT 11.5 months
Median CD34 dose 5.56E + 06 cell dose/kg259
SUCCESSFUL STEM CELL MOBILIZATION AND ENGRAFTMENT IN
HEAVILY PRETREATED MULTIPLE MYELOMA PATIENTS WITH PRIOR
HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTA-
TION
Khaled, Y., Solh, M., Lamontagne, D., Batista, A., Sullivan, J., Chan-
Fong, S., Fondaw, M., Reddy, V. Florida Cancer Institute, Orlando, FL
Salvage second autologous transplantation for patients with re-
lapsed multiple myeloma (MM) after prior autologous transplanta-
tion has shown to be beneficial in particular if the first remission isMobilization
Regimen
First
Transplant T
ytoxan/G-CSF Single
ytoxan/G-CSF Planned
Tandem
ytoxan/G-CSF Single
-CSF Single
, Bortezomib, Dex.; Thal, Th
ib.longer than 12-18 months. In addition second salvage autologous
transplant may be used in the contest of progressive refractory mye-
loma for temporarily disease control or for hematopoietic reconsti-
tution after prior extensive therapy. Customarily, patients with
multiple myeloma who received prior alkylating agents or autolo-
gous transplantation with high dose Melphalan are considered non
transplant candidate because of the deleterious effects on stem cell
collection. Plerixafor is a chemokine receptor -4- antagonist which
is approved by FDA for use in combination with G-CSF for mobili-
zation of CD34+ stem cells in patients with NHL and multiple my-
eloma. We have explored the feasibility of Plerixafor and G-CSF in
stem cell collection for second salvage autologous transplantation in
4 consecutive patients with multiple myeloma who underwent prior
extensive therapy including prior autologous transplantation with
Melphalan-200. Patient characteristics, chemotherapy used and in-
terval between first and second salvage transplant are shown in
Table 1. All Patients received GCSF at dose of 10 mcg/KG for 4
days in AM, Plerixafor on the evening of the 4th night and subsequent
nights prior to apheresis at a dose of 0.24 mg/kg. The number of
apheresis procedures were 2 in two patients and 3 in two patients.
The number of CD34 + cells collected were 4.25, 3.06, 3.63, 3.78
million cells/Kg. All the patients engrafted successfully after the sec-
ond transplant. Neutrophils engraftement were at day 10, 12, 12 and
11 while platelet engraftment were at day 10, 15, 32 and 19 respec-
tivlely for the four patients.
Our Data shows the feasibility of stem cell collection in heavily
pretreated MM patients including high dose Melphalan and autolo-
gous stem cell transplantation. Prospective studies are needed to
confirm such feasibility. Such approach may have future clinical ap-
plication in eliminating minimal residual disease after the first autol-
ogous transplant when used in MM patients with planned upfront
tandem autologous transplant.
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A TREOSULPHAN BASED REDUCED TOXICITY CONDITIONING PROTO-
COL FOR THALASSAEMIA MAJOR
Raj, R., Munirathnam, D., Khandelwal, V., Sri, K., Bhushan, V.,
Kumar, M., Lakshmanan, V. Apollo Speciality Hospital, Chennai, Tamil-
nadu, India
We present data comparing two conditioning protocols for beta
thalassaemia major in patients treated in our unit from 2005 to
2011.Twenty children aged between 2 and 9 years were treated using
oral busulphan 16 mg/kg/day with cyclophosphamide 200 mg/kg/
day were assigned to group one. Twenty children aged between 1
and 14 years were treated using thiotepa 8 mg/kg, treosulphan 42
gm/m2 and fludarabine 160 mg/m2 were assigned to group two.
Datawas analysed retrospectively forLucarelli class,mucositis, blood
product requirement, need for parenteral nutrition, engraftment and
transplant relatedmortality. Group one had 4 class I, 10 class II and 6
class III patients between age groups 1 to 14 years. Mucositis was
grade two and above in 11 children and they needed partial parenteralype
Maintenance/Relapse
treatment Re-Induction
Interval between
transplants (Years)
Thalidomid then
Lenalidomide
maintenance
RVD  3 8.57
Dex/Thal followed
by Bro/Doxil
MPV-Rituximab 4.77
Dex/Thal then
RVD3 then
VD-PACE
MPV-Rituximab 2 4.43
Lenalidomide
maintennace for
15 months
RVD  4,
VD-PACE 2
1.75
alidomide; MPV, Melphalan, Prednisone , Bortezomib; PACE, Cisplatin,
